Wednesday, December 14, 2016

BRIEF-Intercept says European Commission grants Ocaliva marketing authorization

* European Commission grants Intercept's Ocaliva

(obeticholic acid) marketing authorization for the treatment of

primary biliary cholangitis

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)